We are live on
!
Find out more
RCI
Ridgeback Capital Investments Portfolio holdings
AUM
$560K
This Fund
S&P 500
This Quarter
Est. Return
-44.98%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$37M
AUM Growth
–
Cap. Flow
+$44.4M
Cap. Flow
% of AUM
120.01%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
1
New
1
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Karyopharm Therapeutics
KPTI
|
+$44.4M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
LPARFS
SC
ZIMP
XS
B
AMG
SFG
CIM
Ridgeback Capital Investments's Q4 2018 Portfolio in Review
Q4 2018 is the first quarter with a 13F filing on record for Ridgeback Capital Investments, which disclosed 1 position worth $37M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Karyopharm Therapeutics: 263,013 shares worth $37M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Ridgeback Capital Investments's largest Q4 2018 buy was Karyopharm Therapeutics: 263,013 shares worth $37M.
- Ridgeback Capital Investments's ten largest holdings make up 100% of its $37M portfolio in Q4 2018.
- Ridgeback Capital Investments disclosed 1 position in Q4 2018, its first 13F filing on record.
Based on Ridgeback Capital Investments's 13F filing for Q4 2018, filed 14 Feb 2019.